drugset / Trial / NCT01092702

Varenicline For Smokers In Recovery From Alcohol Dependence

NCT01092702

Phase 2/3 Completed 32 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

The goal of this proposal is to explore the potential effectiveness of varenicline to treat tobacco dependence among recovering alcoholic smokers who, as a group, are at high risk for tobacco-caused morbidity and mortality. In this open-label phase II clinical trial, we are proposing to enroll 32 recovering alcoholic smokers who are motivated to stop smoking. After the initial up titration of varenicline in week 1, all 32 subjects will receive a total of 2 mg/day of varenicline for 12 weeks. In addition to receiving varenicline, all subjects will receive brief behavioral counseling and our standard intervention at each visit during participation in the study.

Timeline

Start
2008-04
Primary completion
2008-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 1 mg

Indications